CB-010 Phase 1 data: 94% ORR, 69% CR in r/r B-NHL; 44% CR ≥6 months; cash ~$292.5M

Caribou Biosciences, Inc.

CB-010 achieved 94% ORR (15/16) and 69% CR (11/16) in r/r B-NHL patients in ANTLER Phase 1 dose escalation.
44% of patients (7/16) had CR at ≥6 months; longest CR maintained at 24 months.
LBCL subgroup (N=10): 90% ORR, 70% CR, 50% CR at ≥6 months; longest CR 18 months.
CB-010 generally well tolerated; no Grade 3+ CRS or GvHD; common Grade 3+ events: thrombocytopenia (69%), neutropenia (56%).
Preliminary cash, cash equivalents & marketable securities ~$292.5M as of June 30, 2023; enrolling 2L LBCL in dose expansion.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Caribou Biosciences, Inc. reported preliminary financial results for the three and six months ended June 30, 2023.

Period: the three and six months ended June 30, 2023
Result: preliminary results

Exact text from the filing

Preliminary unaudited cash, cash equivalents, and marketable securities as of June 30, 2023 Caribou Biosciences, Inc. (the “Company”) is providing certain preliminary financial results. On a preliminary unaudited basis, the Company expects its cash, cash equivalents, and marketable securities as of June 30, 2023 to be approximately $292.5 million.

View on SEC.gov

Browse all earnings releases →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000087

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.